Alfuzosin

• Benign Prostatic Hyperplasia (BPH)
• Urinary Symptoms from BPH
• Lower Urinary Tract Symptoms

Alfuzosin (brand name Uroxatral) is a uroselective alpha-1 adrenergic receptor blocker prescribed to relieve the bothersome lower urinary tract symptoms of benign prostatic hyperplasia. It is intended for adult men with an enlarged prostate who experience weak stream, hesitancy, incomplete emptying, frequency, urgency, or nocturia (waking at night to urinate). By relaxing prostatic and bladder neck smooth muscle, alfuzosin reduces dynamic outflow obstruction without shrinking the gland itself. This makes it a symptom-focused therapy that typically begins working within the first one to two weeks, with continued benefit accruing over four to eight weeks. Compared with older nonselective alpha-blockers used historically for hypertension, alfuzosin was designed with relative selectivity for lower urinary tract receptors, which translates clinically into fewer marked vascular effects.

Mechanism of Action

Alfuzosin selectively antagonizes alpha-1 adrenergic receptors concentrated in the prostate gland, prostatic capsule, prostatic urethra, and bladder neck. In benign prostatic hyperplasia, sympathetic tone in these tissues is upregulated, contributing to the dynamic component of urinary obstruction independent of static prostate enlargement. Static obstruction reflects the physical bulk of glandular and stromal tissue; dynamic obstruction reflects smooth muscle contraction under sympathetic control, and it is this second component that alpha-blockers reverse. Blocking alpha-1A receptors lowers smooth muscle tension, decreases urethral resistance, and improves urinary flow rates as measured by uroflowmetry. Compared with older nonselective alpha-blockers, alfuzosin demonstrates relative functional uroselectivity, which translates clinically into less marked drops in standing blood pressure and a lower incidence of dose-limiting orthostatic hypotension. The extended-release formulation maintains steady plasma levels through a 24-hour dosing interval, which further smooths the cardiovascular profile and avoids the peaks responsible for first-dose syncope. Detailed pharmacology is summarized in the FDA prescribing information.

Clinical Use

Alfuzosin is a first-line option for symptomatic BPH, particularly when symptoms are moderate to severe on the International Prostate Symptom Score (IPSS, a validated questionnaire that grades bother from 0 to 35). Within the alpha-blocker class, it shares a similar efficacy profile with tamsulosin, silodosin, doxazosin, and terazosin; the choice often depends on cardiovascular comorbidities, ejaculatory side-effect tolerance, drug interaction profile, and cost. Alfuzosin and the older agents doxazosin and terazosin are less likely than tamsulosin or silodosin to produce retrograde ejaculation, which can matter to sexually active patients. Men with significantly enlarged glands (typically over 40 mL) or elevated PSA may benefit from combination therapy with a 5-alpha-reductase inhibitor such as finasteride or dutasteride, which addresses the static component of obstruction and reduces the risk of acute urinary retention and BPH-related surgery over years. Alfuzosin is not an antihypertensive and should not be used to treat blood pressure in isolation. Patients with significant overactive bladder symptoms in addition to obstruction may benefit from a combination of alfuzosin with a beta-3 agonist such as vibegron, used cautiously to avoid retention. For a broader look at urology services, see our urologic and genitourinary care page.

How to Take It

The standard dose is one 10 mg extended-release tablet once daily, swallowed whole, taken immediately after the same meal each day. Food materially increases bioavailability, so consistency matters more than the specific meal chosen; many patients find dinner the most reliable choice. Tablets must not be crushed, split, or chewed; doing so disrupts the controlled-release matrix and risks an exaggerated initial peak with hypotension. If a dose is missed, skip it and resume the regular schedule the next day rather than doubling up. Many men notice modest improvement in urinary flow within the first week or two, with peak benefit by four to eight weeks. The first several doses may produce mild dizziness, especially when standing quickly; rising slowly from bed or a chair during the first week is a sensible precaution, as is avoiding hot showers, alcohol, and rapid changes in posture early on. Store tablets at room temperature, away from moisture and heat. Discontinuing alfuzosin abruptly does not produce withdrawal but does allow symptoms to return within days as smooth muscle tone normalizes.

Monitoring and Follow-Up

No specific laboratory monitoring is mandated, but a baseline check is reasonable, especially in older men with multiple medications. Reassess symptoms with the IPSS questionnaire at four to twelve weeks, then annually. Blood pressure should be measured shortly after initiation, particularly in patients on other antihypertensives or PDE5 inhibitors used for erectile dysfunction. Liver enzymes are worth checking if there is any baseline hepatic concern, since alfuzosin is hepatically metabolized; our overview of common lab panels explains what these values mean. Periodic prostate-specific antigen and digital rectal exam remain part of routine BPH follow-up, since alpha-blockers do not alter the natural progression of prostate growth or change PSA values, unlike 5-alpha-reductase inhibitors which roughly halve PSA after six months and require a doubling correction when interpreting screening values. A post-void residual ultrasound can be useful when symptoms are mixed or worsening, to rule out emerging incomplete emptying that may signal progression.

Special Populations

Elderly men, who represent the majority of users, tolerate alfuzosin reasonably well, but starting dose is unchanged and orthostatic precautions still apply, particularly in those on diuretics or vasodilators. Severe renal impairment has not been thoroughly studied, so caution is advised in patients with eGFR below 30. Mild hepatic impairment requires no adjustment, but moderate to severe hepatic dysfunction is a contraindication because plasma levels rise substantially and risk for hypotension and QT prolongation increases. Alfuzosin is not indicated in women or pediatric patients. Patients planning cataract surgery must inform their ophthalmologist about current or prior alpha-blocker use because of the risk of intraoperative floppy iris syndrome (IFIS), which can complicate the procedure and increase risk of capsular rupture even after the medication is stopped. Concurrent use with strong CYP3A4 inhibitors such as ketoconazole, itraconazole, or ritonavir is contraindicated; combination with PDE5 inhibitors such as sildenafil or tadalafil should be approached with attention to symptomatic hypotension.

Drug Interactions and Lifestyle Considerations

Beyond the formal CYP3A4 interactions, several practical considerations affect day-to-day use. Grapefruit and grapefruit juice modestly inhibit intestinal CYP3A4 and may increase alfuzosin exposure; while not strictly forbidden, large or daily intake should be avoided. Alcohol potentiates the orthostatic effect of alpha-blockers, particularly in the first weeks, and saunas, hot tubs, and prolonged hot showers can amplify vasodilation and trigger lightheadedness. Patients on antihypertensive regimens including beta-blockers, calcium channel blockers, ACE inhibitors, ARBs, or diuretics may notice additive blood pressure lowering and benefit from a check of standing pressures within a few weeks of starting alfuzosin. Nitrate-containing medications used for angina pose a particular concern when combined with both alfuzosin and PDE5 inhibitors. Decongestants containing pseudoephedrine or phenylephrine can pharmacologically antagonize alpha-blockade and worsen urinary symptoms transiently. For men with mixed urinary symptoms, layering an antimuscarinic such as oxybutynin or a beta-3 agonist on top of alfuzosin can help with urgency and frequency, but post-void residuals should be checked because of additive retention risk. Sleep position adjustments and limiting evening fluids often supplement medication benefit for nocturia. Long-term adherence is a recurring issue: many men discontinue alpha-blockers within the first year due to cost, perceived inadequate benefit, or concerns about ejaculatory or vasomotor side effects, so ongoing dialogue about realistic expectations and the natural history of BPH is part of every follow-up visit. Lifestyle measures including weight management, treatment of obstructive sleep apnea, and limiting bladder irritants such as caffeine and alcohol all contribute to symptom control, as discussed in our healthy aging guide.

When to Contact Your Doctor

Call promptly for fainting or near-fainting, severe dizziness, chest pain, palpitations, or a painful erection lasting more than four hours (priapism is a urologic emergency that can cause permanent damage if not treated within hours). Sudden inability to urinate, persistent or worsening urinary symptoms after several weeks of therapy, or signs of allergic reaction such as facial swelling and difficulty breathing also warrant urgent evaluation. Yellowing of the skin or eyes, dark urine, or right upper quadrant pain may signal hepatotoxicity and should prompt a call. New chest discomfort, syncope on exertion, or worsening edema deserves prompt assessment to rule out cardiovascular contributors that could be exacerbated by alpha-blockade.

If you are experiencing bothersome urinary symptoms, want to discuss whether alfuzosin or an alternative therapy is right for you, or need a baseline BPH evaluation, contact us or schedule a visit with our team.